Mode
Text Size
Log in / Sign up
N/A N=80 Randomized Single-blind Treatment

Comparison of Ultrasound Guided Versus Blind Corticosteroid Injection for Trochanteric Bursitis

Bursitis

Enrolled (actual)
80
Serious AEs
Results posted
Jan 2021
Primary outcome: Primary: Pain Intensity Measured on Visual Analog Scale (VAS)

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Trochanter bursa injections (Procedure); Ultrasound (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
West Virginia University
Primary completion
Apr 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Intensity Measured on Visual Analog Scale (VAS)
SECONDARY
Disability Measured on Becks Disability Scale
SECONDARY
Adverse Effects
SECONDARY
Pain Improvement

Summary

Trochanteric bursitis is a common condition, effecting 20% of the population. \Most with trochanteric bursitis experience chronic intermittent or continuous hip pain at and around the greater trochanter. The cause of trochanteric bursitis is believed to be a result of inflammation of the bursa, though this has not been confirmed. Accordingly, the use of corticosteroid injections has been shown to provide considerable relief. However, routine "blind" injections, those performed without the aid of imaging, such as fluoroscopy, have shown limited success in the appropriate needle placement. Fortunately, blind injections have yielded positive results in majority of the cases. Additionally, the use of fluoroscopy has not shown to improve clinical outcome for trochanter bursa injections. Although the use of fluoroscopy has not shown positive benefit, other modes of imaging, such as ultrasound have not been studied and may be more useful. Fluoroscopy allows for bony-landmark based injections. Ultrasound allows for direct visualization of the soft tissue structures such as the bursa and has gained significant support for use in musculoskeletal injections. This prospective blinded study's aim is to evaluate, if any, the benefit of an ultrasound guided injection and whether ultrasound should be routinely used during trochanter bursa injections.

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of trochanteric bursitis
  • 18 years of age or older when written informed consent is obtained
  • Signed Institutional Review Board (IRB) approved informed consent form

Exclusion Criteria

  • Allergy to triamcinolone or bupivicaine
  • Coagulopathy
  • Active Infection
  • Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or complete study assessments
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02221817). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search